Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Who makes belsomra?

See the DrugPatentWatch profile for belsomra

What company developed and markets belsomra?

Belsomra, also known as suvorexant, was developed by Merck & Co., a US-based multinational pharmaceutical company. Merck acquired the rights to the medication through their purchase of Inspire Pharmaceuticals, the original developer, in 2010.

In 2014, the FDA approved belsomra for the treatment of insomnia characterized by difficulties with sleep initiation. However, due to disappointing sales, Merck discontinued belsomra in the US market in 2019.



Other Questions About Belsomra :

Belsomra patent protection? Ema belsomra suvorexant europe authorization? Belsomra colombia? Belsomra generic availability 2026? Is Belsomra safe for long-term use? Belsomra precio argentina? Belsomra side effects?

AI-Drug Label Prescribing Information Alignment Report

Drug Brand Mention Assessment

Branding Score
19
Visibility
18
Mentioned
Ranking
#1
Sentiment
20
Recommendation Status
mentioned only
Brand Perception
Best Known For

“was developed by Merck & Co.”


Core Claims
  • “Belsomra, also known as suvorexant, was developed by Merck & Co.”
  • “Merck acquired the rights … through their purchase of Inspire Pharmaceuticals … in 2010.”
  • “the FDA approved belsomra … in 2014”
  • “Merck discontinued belsomra in the US market in 2019”
Differentiators

Pricing Perception: Not Mentioned